Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-18 (trafermin) regenerative therapy for external auditory meatus soft tissue defects
jRCT2051230028Active, not recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of trafermin in External auditory canal defect, sponsored by Nobelpharma Co., Ltd. Primary endpoints: Complete closure of the defect at 16 weeks after the final regenerative procedure and Safety: adverse events and related assessments. Started May 2023; status: active, not recruiting.
02
Drugs
trafermin
03
Conditions
External auditory canal defect
Beyond the preview
Go deeper on jRCT2051230028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230028.